For research use only. Not for therapeutic Use.
YD23 is a SMARCA2 PROTAC. YD23 induces degradation of SMARCA2, which is synthetic lethal to SMARCA4. Moreover, YD23 decreases chromatin accessibility at enhancers of a number of genes including cell cycle and cell growth regulatory genes. YD23 reduces chromatin accessibility only in SMARCA4 deficient cells mechanistically[1][2].
| Catalog Number | I041365 |
| CAS Number | 2951015-29-3 |
| Synonyms | 4-[2-[2-[4-[[4-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]piperazin-1-yl]methyl]-2-fluorophenoxy]ethoxy]ethylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| Molecular Formula | C38H39FN8O7 |
| Purity | ≥95% |
| InChI | InChI=1S/C38H39FN8O7/c39-26-20-23(22-45-13-15-46(16-14-45)30-21-28(43-44-35(30)40)24-4-1-2-7-31(24)48)8-10-32(26)54-19-18-53-17-12-41-27-6-3-5-25-34(27)38(52)47(37(25)51)29-9-11-33(49)42-36(29)50/h1-8,10,20-21,29,41,48H,9,11-19,22H2,(H2,40,44)(H,42,49,50) |
| InChIKey | DMUYROJVOXZRNE-UHFFFAOYSA-N |
| SMILES | C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCOCCOC4=C(C=C(C=C4)CN5CCN(CC5)C6=CC(=NN=C6N)C7=CC=CC=C7O)F |
| Reference | [1]. Kotagiri S, et al. Novel SMARCA2 degrading bifunctional molecules as therapeutics in SMARCA4 mutant lung cancer[J]. Cancer Research, 2023, 83(7_Supplement): 1138-1138. [2]. Kotagiri S, et al. Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant tumors[J]. Cancer Research, 2023, 83(7_Supplement): 6289-6289. |
